PMID- 29250057 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20191120 IS - 1664-3224 (Print) IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 8 DP - 2017 TI - Update on Dendritic Cell-Induced Immunological and Clinical Tolerance. PG - 1514 LID - 10.3389/fimmu.2017.01514 [doi] LID - 1514 AB - Dendritic cells (DCs) as highly efficient antigen-presenting cells are at the interface of innate and adaptive immunity. As such, they are key mediators of immunity and antigen-specific immune tolerance. Due to their functional specialization, research efforts have focused on the characterization of DCs subsets involved in the initiation of immunogenic responses and in the maintenance of tissue homeostasis. Tolerogenic DCs (tolDCs)-based therapies have been designed as promising strategies to prevent and control autoimmune diseases as well as allograft rejection after solid organ transplantation (SOT). Despite successful experimental studies and ongoing phase I/II clinical trials using autologous tolDCs in patients with type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and in SOT recipients, additional basic research will be required to determine the optimal DC subset(s) and conditioning regimens for tolDCs-based treatments in vivo. In this review, we discuss the characteristics of human DCs and recent advances in their classification, as well as the role of DCs in immune regulation and their susceptibility to in vitro or in vivo manipulation for the development of tolerogenic therapies, with a focus on the potential of tolDCs for the treatment of autoimmune diseases and the prevention of allograft rejection after SOT. FAU - Obregon, Carolina AU - Obregon C AD - Department of Medicine, Transplantation Centre and Transplantation Immunopathology Laboratory, Service of Immunology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. FAU - Kumar, Rajesh AU - Kumar R AD - Department of Medicine, Transplantation Centre and Transplantation Immunopathology Laboratory, Service of Immunology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. FAU - Pascual, Manuel Antonio AU - Pascual MA AD - Department of Medicine, Transplantation Centre and Transplantation Immunopathology Laboratory, Service of Immunology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. AD - Department of Surgery, Transplantation Centre, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. FAU - Vassalli, Giuseppe AU - Vassalli G AD - Departement coeur-vaisseaux, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. AD - Fondazione Cardiocentro Ticino, Swiss Institute of Regenerative Medicine (SIRM), Lugano, Switzerland. FAU - Golshayan, Dela AU - Golshayan D AD - Department of Medicine, Transplantation Centre and Transplantation Immunopathology Laboratory, Service of Immunology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. AD - Department of Surgery, Transplantation Centre, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20171120 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 PMC - PMC5715373 OTO - NOTNLM OT - autoimmune diseases OT - immunotherapy OT - solid organ transplantation OT - tolerance OT - tolerogenic dendritic cells EDAT- 2017/12/19 06:00 MHDA- 2017/12/19 06:01 PMCR- 2017/01/01 CRDT- 2017/12/19 06:00 PHST- 2017/07/12 00:00 [received] PHST- 2017/10/26 00:00 [accepted] PHST- 2017/12/19 06:00 [entrez] PHST- 2017/12/19 06:00 [pubmed] PHST- 2017/12/19 06:01 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2017.01514 [doi] PST - epublish SO - Front Immunol. 2017 Nov 20;8:1514. doi: 10.3389/fimmu.2017.01514. eCollection 2017.